✦ LIBER ✦

Bladder-Sparing Treatment Modalities in the Management of Invasive Bladder Cancer

✍ Scribed by Levent N. Türkeri; Markus Kuczyk

Book ID: 118440303
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 79 KB
Volume: 4
Category: Article
ISSN: 1569-9056
DOI: 10.1016/j.eursup.2005.01.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Organ-Sparing Treatment in Muscle-Invasi

Organ-Sparing Treatment in Muscle-Invasive Bladder Cancer

✍ Jürgen Dunst; Andrea Diestelhorst; Reinhard Kühn; Arndt-Christian Müller; Hans-J 📂 Article 📅 2005 🏛 Springer 🌐 German ⚖ 328 KB

Combined modality treatment with bladder

Combined modality treatment with bladder preservation for muscle invasive bladder cancer

✍ Magdy A. Sabaa; Osama M. El-Gamal; Mohamed Abo-Elenen; Amr Khanam 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 254 KB

Combined modality therapy for the treatm

Combined modality therapy for the treatment of invasive bladder cancer

✍ William U. Shipley 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 124 KB

Combined modality therapy for the treatm

Combined modality therapy for the treatment of invasive bladder cancer

✍ William U. Shipley; Anthony L. Zietman 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Updated results of bladder-sparing trimo

Updated results of bladder-sparing trimodality approach for invasive bladder cancer

✍ Almudena Zapatero; Carmen Martin de Vidales; Ramón Arellano; Gloria Bocardo; Mar 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 731 KB

Bladder-sparing, combined-modality appro

Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer : A multi-institutional, long-term experience

✍ Sisto Perdonà; Riccardo Autorino; Rocco Damiano; Marco De Sio; Brunello Morrica; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB

## Abstract ## BACKGROUND. The authors evaluated their long‐term experience with combined‐modality, conservative treatment in patients with muscle‐invasive bladder cancer. ## METHODS. In total, 121 patients with T2, T3, or T4 bladder cancer (mean age, 63 years; ratio of men to women, 3:1) underw